Loading...
•
Dec 31, 2021
Rhythm Pharmaceuticals Q4 2021 Earnings Report
Reported financial results and provided a business update.
Key Takeaways
Rhythm Pharmaceuticals reported their Q4 2021 financial results, highlighting the commercial availability of IMCIVREE and progress in clinical development and regulatory efforts.
IMCIVREE fourth quarter sales were $1.8M.
First commercial sales of IMCIVREE in Germany and France expected in 2Q2022.
Enrollment completed in Phase 2 trial evaluating setmelanotide in patients with hypothalamic obesity.
A potential U.S. approval for IMCIVREE in BBS and Alström syndrome now set for June.
Rhythm Pharmaceuticals
Rhythm Pharmaceuticals
Forward Guidance
Rhythm expects that its existing cash, cash equivalents and short-term investments as of December 31, 2021 will be sufficient to fund its operating expenses and capital expenditure requirements into at least the second half of 2023.